

Source details

F1000Research	1			CiteScore 2021 5.0	Ū
Scopus coverage year	s: from 2012 to	Present			
Publisher: Taylor & F				SJR 2021	Ū
E-ISSN: 2046-1402				0.939	0
Subject area: (Pharmae	cology, Toxicology and F	Pharmaceutics: G	eneral Pharmacology, Toxicology and Pharmaceutics		
Biochen Source type: Journal		lecular Biology: C	General Biochemistry, Genetics and Molecular Biology $ ightarrow$ View all \checkmark	SNIP 2021 1.010	(i)
Source type. Journal					
View all documents >	Set document aler	rt 💾 Save	to source list Source Homepage		
CiteScore CiteScor	re rank & trend	Scopus co	ontent coverage		
CiteScore 2021 c		eceived in 2018	-2021 to articles, reviews, conference papers, book chapters and data he number of publications published in 2018-2021. Learn more >		×
CiteScore 2021	~		CiteScoreTracker 2022 ①		
15,170	Citations 2018 - 1	2021	11,602 Citations to date		
$5.0 = \frac{3.056 \text{ D}}{3.056 \text{ D}}$	ocuments 2018 -	2021	4.7 =		
Calculated on 05 May, 2022			Last updated on 05 October, 2022 • Updated monthly		
CiteScore rank 20	21 🛈				
Category	Rank Percent	ile			
Pharmacology, Toxicology and Pharmaceutics	#11/74	85th			
General Pharmacology, Toxicology and Pharmaceutics					
Biochemistry, Genetics and Molecular Biology	#65/204	68th			

View CiteScore methodology > CiteScore FAQ > Add CiteScore to your site c°

Q

About Scopus

What is Scopus Content coverage Scopus blog Scopus API Privacy matters

Language

日本語版を表示する **查看简体中文版本** 查看繁體中文版本 Просмотр версии на русском языке

Customer Service

Help Tutorials Contact us

ELSEVIER

Terms and conditions ${\mathbin{\,\triangledown}\,}$ ${\mathbin{\,\square}\,}$ Privacy policy ${\mathbin{\,\triangledown}\,}$

 $\label{eq:copyright} \textcircled{C} Elsevier B.V \ensuremath{\,\boxtimes}\ . All rights reserved. Scopus @ is a registered trademark of Elsevier B.V. \\ We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies \ensuremath{\!\neg}\ . \\ \end{aligned}$

RELX


										S RANKINGS
SJR	Scimago Journal & Country Rank							Enter Journal	Title, ISSN or Publisher Name	Ω,
		Home	Journal Rankings	Country Rankings	Viz Tools	Help	About Us			


COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
United Kingdom	Biochemistry, Genetics and Molecular Biology Biochemistry, Genetics and Molecular Biology (miscellaneous) Immunology and Microbiology (miscellaneous) Medicine Medicine Medicine (miscellaneous) Pharmacology, Toxicology and Pharmaceutics Pharmaceutics (miscellaneous)		72
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	20461402	2012-2021	Homepage
			How to publish in this journal
			research@f1000.com

SCOPE

F1000Research publishes articles and other research outputs reporting basic scientific, scholarly, translational and clinical research across the physical and life sciences, engineering, medicine, social sciences and humanities. F1000Research is a scholarly publication platform set up for the scientific, scholarly and medical research community; each article has at least one author who is a qualified researcher, scholar or clinican actively working in their speciality and who has made a key contribution to the article. Articles must be original (not duplications). All research is suitable irrespective of the perceived level of interest or novelty; we welcome confirmatory and negative results, as well as null studies. F1000Research publishes different type of research, including clinical trials, systematic reviews, software tools, method articles, and many others. Reviews and Opinion articles providing a balanced and comprehensive overview of the latest discoveries in a particular field, or presenting a personal perspective on recent developments, are also welcome. See the full list of article types we accept for more information.

 $\ensuremath{\bigcirc}$ Join the conversation about this journal





Metrics based on Scopus® data as of April 2022

()

Loading comments...

	Scopus
	@ScimagoJR
Scimago Lab, Copyright 2007	

EST MODUS IN REBUS Horatio (Satire 1.1.106)

Edit Cookie Consent



Home » Advisory Board

Advisory Board

The Advisory Board of F1000Research comprises a large group of leading experts across biology and medicine. They do not act as Editors in the traditional sense (they do not handle manuscripts or make decisions to accept or reject a paper), but they provide strategic input on the direction we should take with F1000Research. They occasionally advise us on issues arising with specific articles, and many members of the board also review for us.



B	lan Beales
	Nelson Bennett
	Avri Ben-Ze'ev
	Benedikt Berninger
	Eric Beyer
	Azra Bihorac
	Daniel Bikle
	Kevin J Black
	Chellakkan Selvanesan Blesson
	Erin Aiello Bowles
	Bruce Brew
С	David Catcheside
	Andrew Chalmers
	Tak Mao Chan
	Karen Chapman
	Declan Chard
	Walter Chazin
	Jonathan Chernoff
	Cheng-Ming Chiang
	Ryan Chisholm
	Wei-Sheng Chong
	Sandra Citi
	Vitaly Citovsky
	Tim Clark
	James Coker
	Giuseppe Colloca
	William Colmers
	Jason Crawford
	David Criddle
D	
D	Ira Daar
	Linda Dagi
	Blossom Damania
	Eric Dannaoui
	Vinicio de Jesus Perez
	Sharon DeMorrow
	Gonzalo G de Polavieja

Saskia de Wildt Harriet de Wit

Annette Dolphin

Lucy Donaldson Sylvie Doublié Paschalis-Thoma Doulias Crislyn D'Souza-Schorey James Duffin Janice Du Mont

Sharyn Endow Markus Engstler Sam Enna

Erim Erdem

E

E

Alastair Ferguson Gerardo Ferrara Richard Festenstein Thomas Finger Céline Fiset Heike Fölsch Steven Frank Bernd Fritzsch

Gus Gazzard

G

Jozef Gécz Robert Gerlai Ivan Gerling Carole Goble Richard Gomer Andrew Goryachev John Greenspan Guy Griebel W Sue Griffin Elizabeth Grove Jaime Grutzendler Wei Guo

Adam Hartman
 Johannes Hell
 Winston Hide
 Stephen Hoffman
 Stephen Holgate
 Thorsten Hoppe
 Wolfgang Huber
 Arthur Hurwitz

Radu Iliescu Robert Insall Harry Ischiropoulos

Jan Jakobsson

Guilhem Janbon

J

Wael Kafienah

Chaya Kalcheim Lynn Kamerlin Mikhail Kazachkov Johannes S Kern Jean-Pierre Kinet Edward Kipreos Fenella Kirkham Gordon Klein Alisa Koch Amos Korczyn Benoit Kornmann Jan Kucera Anuj Kumar Saravana Kumar

Eileen Lafer

Hans Lassmann Mario Lebendiker John Lee Laurel Lenz Simon Levin Stefan Linder Ton Lisman Creighton M Litton Hartmut Lode Theresa Lu Robyn Lucas Ben Lugtenberg Paul Lyons

Μ

Roberto Maggi Martin Marinus M Rashad Massoud Jocelyn McDonald Robert McPeek Anthony Means Julien Mendlewicz Arthur Mercurio Ralph Mistlberger Ali Mobasheri David Moher Randall Moon Carlos Morel Dimitrios Morikis Nicola Mulder

Corey Nislow

×

Chiadi Onyike

Stephen Pinneia

Michel Pohl Simon Portsmouth David Potter Chaim Putterman



Adam Ratner Ana Recober

> Victor Reus José Luis Riechmann Karin Romisch Vincent Rotello Barry Rouse Gloria Rudenko James Russell

S

Philippe Saas Paul R Sanberg Alan Schechter Werner Scheithauer Tamar Schlick Thomas Schnider Alfons Schnitzler Irene Schulz Michael Sendtner Andrew D Sharrocks Nilabh Shastri Kazim Sheikh Andrew Shennan Xiao Shifu Chiara Simonelli Helmy Siragy Cassian Sitaru **Richard Smith** H Peter Soyer Pamela Stanley Christoph Stein **Carly Stevens Charles Stevens** Bruno Stieger

Т

Paul-Peter Tak Paul Terry Igor Tetko Jacques Thibodeau Jakub Tolar Peter Tonellato Francis Tsai Takeshi Tsubata Tom Tullius Burkhard Tümmler



ର ≡

Hans van Bokhoven Martin van den Berg Peter Van Endert Dirk van Helden Chandra Verma Jan Vermorken David Voehringer

Claire Walczak
 Nick Ward
 Peter Wark
 Stephen Waxman
 Alan Wein
 Tom Woodcock
 Long-Jun Wu
 Jeremy C Wyatt
 Kevan Wylie



Ζ

Michael B Yaffe Kenneth Yamada Helen Yap Dorothy Yuan

> Yunde Zhao Deyou Zheng Guy Zimmerman Christos Zouboulis

F1000Research

An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.

BROWSE GATEWAYS COLLECTIONS HOW IT WORKS BLOG CONTACT PRIVACY NOTICE RSS



×



нпопанну



Home » Browse Articles

You searched for Muhtarum Yusuf

ARTICLES FACULTY REVIEWS DOCUMENTS POSTERS SLIDES

FILTERS 🗸

1-2 of 2 ARTICLES

CASE REPORT IN metrics

REVISED Case Report: Nasopharyngeal carcinoma has metastasis to the orbit, consequences in anaemia: A paediatric unusual case of Bangladesh. [version 2; peer review: 1 approved]

Mohammad Ashraful Amin, Sabrina Nahin, Atia Sharmin Bonna, Mohammad Delwer Hossain Hawlader

WEAR REVIEWER Muhtarum Yusuf

LATEST VERSION PUBLISHED 30 Sep 2022

RESEARCH ARTICLE metrics

REVISED Correlation between CD44+ cancer stem cell expression and histopathological types of nasopharyngeal carcinoma [version 2; peer review: 2 approved]

Muhtarum Yusuf, Indriyadevi Indra, Sri Herawati Juniati, Yussy Afriani Dewi

I PEER REVIEWERS Farhat Farhat; Mohd Razif Mohamad Yunus

LATEST VERSION PUBLISHED 03 Nov 2021

PUBLISH YOUR RESEARCH



An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.

Q =

BROWSE GATEWAYS COLLECTIONS HOW IT WORKS BLOG CONTACT PRIVACY NOTICE RSS

ð © () Ø



© 2012-2022 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing



RESEARCH ARTICLE



Correlation between CD44+ cancer stem cell expression and histopathological types of nasopharyngeal carcinoma [version 1; peer review: 1 approved, 1 approved with reservations]

Muhtarum Yusuf^{1,2}, Indriyadevi Indra^{1,2}, Sri Herawati Juniati^{1,2}, Yussy Afriani Dewi³

 ¹Otolaryngology, Head, and Neck Surgery, Airlangga University, Surabaya, East Java, 60132, Indonesia
 ²Dr. Soetomo General Teaching Hospital, Surabaya, East Java, 60286, Indonesia
 ³Department of Ear-Nose-Throat, Head and Neck Surgery, Hasan Sadikin Hospital, Padjadjaran University, Jl. Dipati Ukur No.35, Bandung, Jawa Barat, 40132, Indonesia

 First published: 28 Jul 2021, 10:678 https://doi.org/10.12688/f1000research.53643.1
 Latest published: 28 Jul 2021, 10:678 https://doi.org/10.12688/f1000research.53643.1

Abstract

Background: Nasopharyngeal carcinoma (NPC) recurrency rate is still high despite patients receiving complete treatment. The response to treatment may vary depending on the type of histopathology and Epstein-Barr virus, however the mechanism remains unclear. Recent studies have found that there is a relationship between response to treatment and the presence of cancer stem cells (CSCs). CD44+ cancer stem cells may cause cancer cells to be resistant to treatment. Therefore, this cross-sectional study aims to determine the correlation between CD44 + cancer stem cell expression and the histopathological types of NPC.

Method: Samples were obtained from NPC biopsies of type I, II, III patients (based on WHO histopathology criteria), who had not received prior treatment. CD44+ expression was examined using immunohistochemistry methods by staining CD44+ monoclonal antibodies. The degree of CD44+ cell membrane expression was based on the immunoreactive score scale or the Remmele index scale. **Results:** Most histopathological types were WHO type III (21 patients, 50%), followed by type II (18 patients, 42.86%), and type I (3 patients, 7.14%). CD44 + expression on type I showed one patient had moderate positive and two patients had a high-positive expression. In type II, 10 were moderate positive, 11 were moderate positive and nine patients were high-positive. Statistical analysis showed that the CD44+ expression difference between the three histopathology types were not statistically significant.

Conclusion: There were no correlations between CD44 + expression and histopathological type of NPC.



1. Farhat Farhat D, Universitas Sumatera Utara, Medan, Indonesia

2. Mohd Razif Mohamad Yunus ^(D), Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

Any reports and responses or comments on the article can be found at the end of the article.

Keywords

NPC stem cells, CD44 +, nasopharyngeal carcinoma, histopathology, cancer

Corresponding author: Muhtarum Yusuf (muhtarum.yusuf@fk.unair.ac.id)

Author roles: Yusuf M: Conceptualization, Formal Analysis, Investigation, Methodology, Project Administration, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Indra I**: Conceptualization, Data Curation, Formal Analysis, Project Administration, Software, Visualization, Writing – Original Draft Preparation; **Juniati SH**: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Resources, Software, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Afriani Dewi Y**: Conceptualization

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Yusuf M *et al*. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Yusuf M, Indra I, Juniati SH and Afriani Dewi Y. Correlation between CD44+ cancer stem cell expression and histopathological types of nasopharyngeal carcinoma [version 1; peer review: 1 approved, 1 approved with reservations] F1000Research 2021, **10**:678 https://doi.org/10.12688/f1000research.53643.1

First published: 28 Jul 2021, 10:678 https://doi.org/10.12688/f1000research.53643.1

Introduction

Nasopharyngeal carcinoma (NPC) recurrency rate is still high despite patients receiving complete treatment, such as radiotherapy, chemotherapy, or a combination of both. The responses of NPC to therapy varies greatly and might be associated with the type of histopathology. The histological classification of NPC issued by WHO in 1978 includes: (i) type I as *keratinizing squamous carcinoma*, (ii) type II as *non keratinizing squamous carcinoma*, (iii) type III as *non keratinizing squamous carcinoma*, (iii) type III as *undifferentiated carcinoma*.¹ Type II and III World Health Organization (WHO) histopathology types respond more effectively to radiotherapy and have a better locoregional control than type I.² The difference in therapeutic response was associated with the presence of Epstein-Barr virus (EBV) as a causative factor of NPC, but the mechanism remains unclear.³ Recent studies have shown that there is a relationship between therapeutic response and the presence of cancer stem cells (CSCs). The presence of CSCs can cause cancer cells to be resistant to treatment^{4,5} Type II and III WHO histopathology of NPC are closely related to EBV based on the etiology factor of NPC. This was supported by immunoglobulin (IgG and IgA) viral capsid antigen titer increase, early antigen, EBV nuclear antigen (EBNA), however increased titer was not found in type I histopathology of NPC.⁶ A recent study has shown the important role of EBV in NPC stem cells related to the cancer development.⁷

CD44+ molecule is an identification marker of NPC stem cells. The study on NPC with positive EBV cell line C666-1 showed that CD44+ cancer stem cells have the capacity to self-renew, differentiate, initiate tumor cells in *vivo*, and they are highly resistant to 5-fluorouracil therapy.⁸ Ebstein-Barr virus can potentially induced CSCs in EBV-positive NPC by altering the Notch and hedgehog signaling pathways through the *latent membrane protein*-1 (LMP1), LMP2A.^{9,10}

The purpose of this study was to determine the correlation between CD44+ CSCs expression and the histopathological type in the tissue sample of NPC patients who had received treatment at the department of otolaryngology, head, and neck surgery in the general hospital Dr Soetomo Surabaya (RSUD Dr. Soetomo Surabaya). At present this correlation has not been investigated in this teaching hospital. In a clinical setting the results of this study can be used as a predictor biomarker to assess therapeutic response.

Methods

In this cross-sectional study 43 tumor tissue samples (n = 43) that were embedded in paraffin blocks were obtained from NPC patients at the otolaryngology, head, and neck surgery department of the RSUD Dr Soetomo Surabaya. These samples were collected from July to September 2016.

We collected subject, age, ethnicity, stage, histopathology and immunoreactive score (IRS) data consecutively according to the inclusion and exclusion criteria (see underlying data: https://figshare.com/s/cd689f9f2918d71671c6).¹¹ After the patient received the explanation and agreed to participate in the study, we collected the histopathological examination numbers from the nasopharyngeal biopsy. We also obtained the paraffin blocks of the NPC patients for further examination of immunohistochemical staining with CD44 monoclonal antibody (Cell marque, USA, Inteli PATH HLX, model number: IPS0001INTL) at the Anatomical Pathology Laboratory, Faculty of Medicine, Airlangga University, Surabaya. To avoid bias, we used positive controls with paraffin block breast carcinoma. CD44 expression was assessed by an anatomical pathologist from the Department of Anatomical Pathology, Faculty of Medicine, Airlangga University, Surabaya.

Tissue samples included in this study were obtained from patients that had not received radiotherapy, chemotherapy, or a combination of both treatments, in addition to the biopsy material having to be sufficient for immunohistochemistry (IHC) examination. The examination of the IHC method was done with a 400× magnification microscope by staining CD44+ monoclonal antibodies (Cell marque, USA, Inteli PATH HLX, model number: IPS0001INTL).¹² The assessment of CD44+ cell membrane expression levels were based on the IRS scale or the Remmele scale index (Table 1).¹³

Of the 43 samples obtained from the anatomical pathology laboratory, 42 samples met the inclusion criteria, and one damaged sample did not meet the requirements during the immunohistochemical staining process. The population of this study had, 3 people (7.14%) aged 20-29 years, 4 people (9.52%) aged 30-39 years, 14 people (33.33%) aged 40-49 years, 15 people (35.72%) aged 50-59 years and 6 people (14.29%) aged 60-69 years. The male: female ration is 1.3:1, with 24 (57.14%) male patients in the population of the study.

The final score (immunoreactive score/IRS) is the result of multiplying the percentage score of positive cells with the intensity score of brownish-red color on immunoreactive cells.

The degree of expression of CD44 + was categorized as follows: a. Negative expression (-), if the final score is 0

Table 1. CD44 expression based on IRS.

Positive cells percentage	Color reaction intensity
None: 0	
< 10%: 1	No color reaction: 0
11-50%: 2	Low reaction: 1
51-80%: 3	Moderate reaction: 1
>80%: 4	High reaction: 1

Table 2. Distribution of histopathological types.

Histopathology types	N=42	%
WHO type I	3	7.14
WHO type II	18	42.86
WHO type III	21	50

- b. Low expression (+), if the final score is 1 to 3
- c. Moderate expression (++), if the final score is 4 to 6
- d. High expression (+++), if the final score is 7 to 12

NPC histopathology, was divided into three types namely squamous cell carcinoma (WHO type I), nonkeratinizing carcinoma (WHO type II), and undifferentiated carcinoma (WHO type III).³

Data analysis

Spearman's statistical test was done to determine the correlation between CD44+ expression and NPC type of histopathology. CD44+ expression and histopathological type were assessed as an ordinal scale with the significance level <0.05.

Ethical considerations

Patient from the ear nose and throat outpatient unit Dr. Soetomo hospital were given explanation about the research objectives, benefits and examinations carried out. If they were willing to take part in the study, patients were asked to sign a letter of informed consent for the study. Ethical approval (522/Panke.KKE/IX/2016) for this study was obtained by the ethics committee of RSUD Dr Soetomo Surabaya.

Results

The NPC patients' distribution data were based on the type of histopathology (Table 2).

Our results show 21 patients (50%) with WHO-III NPC, followed by 18 (42.86%) with WHO-II, and 3 (7.14%) with WHO-I NPC.

Stage IV was found in 26 (61.90%) patients, followed by stage III in nine (21.43%) patients, stage II in six (14.29%) patients, and stage I in one (2.38%) patient.

CD44 + expression based on the histopathological type of NPC can be seen in Table 4. CD44 + on type I tissue exhibited one moderate positive and two high-positive expressions. In type II tissue, 10 samples showed a moderate positive and eight had high-positive expressions. In type III tissue, one patient had low-positive, 11 had moderate positive and nine had high-positive expressions.

Stage	N = 42	%
Ι	1	2.38
II	6	14.29
III	9	21.43
IV	26	61.90




Figure 1. CD44+ expression on NPC tissue. A. The appearance of a brownish-red color with weak intensity which shows a low-positive. B. Medium intensity brownish-red tint indicating a mid-positive. C. A brownish-red high intensity representing a high-positive (arrows).

CD44+ expression	Histopathologic	Histopathological types			
(IRS scale)	WHO type I	WHO type II	WHO type III		
Low-positive (+)	0	0	1 (4,76%)	1 (2,38%)	
Mid-positive (++)	1 (33.33%)	10 (55.56%)	11 (52.38%)	22 (52.38%)	
High-positive (+++)	2 (66.67%)	8 (44.44%)	9 (42.86%)	19 (45.24%)	
Total	3	18	21		

Table 4. CD44+ expression based on the histopathological type of NPC.

Table 3. Distribution of stage classification.

CD44+ expression with IHC staining with the use of 400x magnification is shown in Figure 1.

Statistical analysis of the correlation between CD44+ expression and the histopathology type of NPC was assessed by Spearman's correlation test (p = 0.925) with (r) = 0.015. This showed that the high expression of CD44 + was obtained in the histopathology of NPC WHO types I, II, III, however the difference was not statistically significant with p > 0.05.

Discussion

The purpose of this study was to explain the relationship between CD44+ cancer stem cell expression with the histopathological type of NPC. This relationship can have an important clinical impact since CD44 can be used as a predictor biomarker for assessment of therapeutic response in NPC.

The findings of this study indicate that the majority (15 patients (35.72%)) of NPC were aged 50-59 years. Research from another center at Dr. RSUP. Kariadi Semarang, majority of the NPC patients, 32.80% (128 people), were in the age group 40-49 years, followed by 31.30% that were aged 50-59 years.¹⁴As the majority of NPC patients in these studies are above the age of 40, it brings into focus that the theory of carcinogenesis is a multifactorial, multistep process with a delay in diagnosis.¹⁵

Patients diagnosed with NPC at a young age tend to experience occupational carcinogenesis. Cancer cells arise from normal cells that undergo transformation to become malignant, due to spontaneous mutation or carcinogen induction. Research has shown that exposure to carcinogens until the emergence of cancer cells can take up to 15-30 years.¹⁶

Patients' sex may be a contributing factor to the incidence of NPC. A total of 24 samples (57.14%) were from male patients in this study, with a ratio of 1.3:1. Research by Roezin (1995) shows that the ratio of NPC sufferers throughout Indonesia was 2.3:1.¹⁷ Research in China indicates similar results (2.5:1).¹⁸ In Asia, high incidence of NPC in men is thought to be caused by differences in living and work habits, as men are more prone to carcinogen exposure such as smoking, use of firewood, exposure to industrial heat and combustion products, which can cause NPC.¹⁹

This research was conducted at Dr. Soetomo Surabaya Hospital, East Java, which is a referral tertiary hospital from Eastern Indonesia, especially the Java region. Therefore, the majority of the research sample are from the Javanese individuals. The research findings also support that the majority of the NPC sufferers (28 samples (66.67%)) were Javanese. Additionally, 61.90% (26 samples) of the samples were NPC stage IV. Research in England also found that stage IV was 52.20%, stage III was 31.30% and stage II was 14.90%, while stage I was not obtained by the study.²⁰ Patients with NPC often seek treatment when this disease is at an advanced stage. Early diagnosis of NPC is challenging as the tumor site is located in a painless area, therefore patients are late to notice this disease.²¹ Additionally the lack of knowledge about the risks of NPC, along with the distance from the place of treatment, and socioeconomic levels adds to the difficulties of early diagnosis.

Cancer stem cells are a subset of tumor cells that have the ability to self-renew and produce new cells to form tumors.²² The function of cancer stem cells as a progenitor and multipotent cell renewal is for proliferation, differentiation and increasing resistance to cancer therapy.^{23,24} NPC has similarities in the type of histopathology and the origin of tumor development between head and neck cancers, including cancer of the oral cavity, pharynx and larynx. In NPC 90% of the histopathological type is squamous cell carcinoma (SCC), which is aggressive and has a high recurrence rate.²⁵ Cluster of differentiation 44 (CD44) is a transmembrane adhesion receptor which is an intermediary for cellular interactions with the tumor microenvirontment that plays a role in the invasion and spread of tumor cells.^{26,27} CD44 expression is associated with cellular invasion and metastasis of cancer cells caused by reorganization of the cytoskeleton to facilitate active migration. The expression of CD44 increases the invasion of cancer cells by increasing in proteases and decreasing the expression and enzymatic activity.²⁶

The IHC findings of this study indicate that the increase in CD44 expression is not in parallel with the histopathological types of WHO in NPC, as one WHO type I sample had moderate positive expression (++), and two samples had strong positive expression (+++). In WHO II NPC type 10 samples showed moderate positive expression (++), and eight samples had strong positive expression (+++). In WHO III NPC type one sample had weak positive expression, 11 samples had moderate positive expression (+++), and nine samples had strong positive expression (+++), no negative CD44 expression was found.

Statistical analysis indicated that the correlations between the expression of CD44 cancer stem cells with the histopathological types of NPC is not significant (p = 0.925). This could possibly be due to the sonic hedgehog (Shh) pathway regulation of the CSCs activities, such as self-renewal.⁷ Positive CD44 expression was found in WHO type I NPC in two patients, WHO II type NPC in ten patients, and WHO III type NPC in nine patients. This suggests that toll-like receptor-3 (TLR3) activates a signaling cascade via the Toll-interleukin-1 receptor [(TIR)] domain-containing-adapter-inducing interferon- β (TRIF), that leads to the activation of the nuclear factor- κ B (NF- κ B) signaling pathway.²⁸ LMP-1 (latent membrane protein-1) also activates NF- κ B and signal transducer and activator of transcription (STAT) signals in EBV-infected epithelial cells via transcription and secretion of interleukin-6 (IL-6).²⁹ Activation of the NF-B signal induces an increase in CD44 expression, which plays a role in the differentiation of NPC cells in WHO I, II and III histopathological types.^{28,29}

The role of CD44 on cancer development has been found in several studies. Ozman et al. (2014) reported that there was a significant relationship between high CD44 expression and perineural invasion and positive lymph nodes in gastric cancer. Research by Simiuniscu et al., (2012) found a weak staining of CD44 expression in poorly differentiated oral SCC, while moderate and strong expressions were markers of moderately and well differentiated carcinoma. This study found weak positive in one undifferentiated carcinoma sample (WHO type III). In the histopathological type of NPC, 90% is aggressive SCC, with a high recurrence cancer rate.²⁵ In the case of oropharyngeal SCC, it was reported that there was a 39.4% decrease in CD44 isoform expression against the CD44 immunoreactivity criteria, and direct relationship between CD44 expression and cervical lymph node metastases, survival, and recurrence was not found in patients with significantly weak/negative CD44 expression. Those who had weak expression of CD44 had worse free survival compared with positive CD44 expression.³⁰

The limitation of this study was in the sample size. Additionally, when IHC staining with CD44 antibody was performed, the paraffin block specimens that were obtained were neither of sufficient nor good quantity to make sample preparations. Finally, this study was not able to evaluate the factors that influence the stage and aggressiveness of NPC.

Conclusion

This study has shown that there is no correlation between CD44+ CSCs expression and the histopathological type of NPC. CD44+ expression can not be used as a predictor marker of therapeutic response. Therefore, there is a need for further studies that take into consideration the stage and metastasis factors, as well as other variables such as CD133 expression.

Data availability statement

Underlying data

Figshare: dataset for The Correlation between CD44+ cancer stem cell expression and histopathological type of nasopharyngeal carcinoma.

DOI: https://figshare.com/s/cd689f9f2918d71671c6.11

The project contains the following underlying data:

CD44_PA_data: Data include subject, age, ethnicity, stage, histopathology and IRS (immunoreactive score).

Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

References

- Robinson M, Suh Y, Paleri V, et al.: Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population. Infect. Agents Can. 2013; 8: 30–36.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Lee AW, et al.: p16 gene therapy: a potentially efficacious modality for nasopharyngeal carcinoma. *Mol Cancer Ther.* 2003; 2, 961–969.
 PubMed Abstract
- Gao W, Li JZ, Ho WK, et al.: Biomarkers for use in monitoring responses of nasopharyngeal carcinoma cells to ionizing radiation. Sensors (Basel), 2012; 12: 8832–8846.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Wang J, Guo LP, Chen LZ, et al.: Identification of cancer stem celllike side population cells in human nasopharyngeal carcinoma cell line. Cancer Res. 2007; 67: 3716–3724.
 PubMed Abstract | Publisher Full Text
- Su J, et al.: Identification of cancer stem-like CD44+ cells in human nasopharyngeal carcinoma cell line. Arch Med Res. 2011; 42: 15–21.
 PubMed Abstract I Publisher Full Text
- Pathmanathan R, et al.: Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am J Pathol. 1995; 146: 1355–1367.
 PubMed Abstract | Free Full Text
- Tsao SW, Tsang CM, Lo KW: Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc L. B Biol Sci. 2017; 372. PubMed Abstract | Publisher Full Text | Free Full Text
- 8. Kumar KPS: Nasopharyngeal carcinoma stem cells. J Biomed Lab Sci. 2009; 21: 35–42.
- Lun SW, Cheung ST, Lo KW: Cancer stem-like cells in Epstein-Barr virus-associated nasopharyngeal carcinoma. Chin J Cancer. 2014; 33: 529–538.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Lun SW, et al.: CD44+ cancer stem-like cells in EBVassociated nasopharyngeal carcinoma. PLoS One. 2012; 7: e52426.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Yusuf M, Indra I, Juniati SH, et al.: Dataset for The Correlation between CD44+ cancer stem cell expression and histopathological type of nasopharyngeal carcinoma. Figshare database. 2021.

- Yu HH, Featherston T, Tan ST, et al.: Characterization of Cancer Stem Cells in Moderately Differentiated Buccal Mucosal Squamous Cell Carcinoma. 2016; 3: 1–9.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Kaemmerer D, et al.: Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol. 2012; 5: 187–194.
 PubMed Abstract | Free Full Text
- Arditawati Y, Prasetyo A: Analisis hubungan antara faktor risiko dengan tipe histopatologi pada karsinoma nasofaring. Progr. Pendidik. Sarj. kedokteran. Fak. Kedokt. Univ. Diponegoro-RSUP Dr. Kariadi, Semarang. 2011: 1–16.
- Prasetyo A: Faktor risiko, eber, iga (ebna1+vcap18), Imp1 dan cd99 sebagai kombinasi baru diagnosis etiologi karsinoma nasofaring. Progr. Dr. Ilmu Kedokt. dan Kesehatan, Fak. Kedokteran, Univ. Gadjah Mada, Yogyakarta. 2014.
- 16. Sukardja IDG: Onkologi Klnik. Airlangga University Pess; 2000.
- 17. Roezin A: **Deteksi dan pencegahan karsinoma nasofaring.** *Dalam: Pencegahan dan deteksi dini penyakit kanker.pdf.* 1995: 274–288.
- Ke K, et al.: Epstein-Barr virus-encoded RNAs as a survival predictor in nasopharyngeal carcinoma. Chin Med J. 2014; 127: 294–299.
 PubMed Abstract
- Chang ET, Adami HO: The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1765–1777.
 PubMed Abstract | Publisher Full Text
- Robinson M, et al.: Oncogenic human papillomavirus-associated nasopharyngeal carcinoma: an observational study of correlation with ethnicity, histological subtype and outcome in a UK population. Infect. Agent. Cancer. 2013; 8: 30.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Tulalamba W, Janvilisri T: Nasopharyngeal Carcinoma Signaling Pathway: An Update on Molecular Biomarkers. Int. J. Cell Biol. 2012; 2012: 594681.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Monroe MM, Anderson EC, Clayburgh DR, et al.: Cancer stem cells in head and neck squamous cell carcinoma. J Oncol. 2011; 2011: 762780. PubMed Abstract | Publisher Full Text | Free Full Text
- Sun L, Cabarcas SM, Farrar WL: Radioresistance and cancer stem cells: survival of the fittest. Cancer stem cell section, loboratory of cancer prevention, center for cancer research. 2016; 2016.

- 24. Zang Z, Filh MS, Nor JE: The biology of head and neck cancer stem cells. Oral Oncol 2012; 4. PubMed Abstract | Publisher Full Text | Free Full Text
- 25. Chai L, et al.: CD44 Expression Is Predictive of Poor Prognosis in Pharyngolaryngeal Cancer: Systematic Review and Meta-Analysis. Tohoku J. Exp. Med. 2014; 232: 9–19. PubMed Abstract | Publisher Full Text
- Chun JW, et al.: The utility of CD44 and D2-40 as a prognostic predictor in invasive carcinomas of the breast. Korean J Clin Oncol. 2013; 9:59–65. Publisher Full Text
- 27. Noroozinia F, Fahmideh A, Yekta Z, *et al.*: **Expression of CD44 and P53 in renal cell carcinoma: Association with tumor subtypes.** Saudi J. Kidney Dis. Transplant. 2014; **25**: 79–84. **PubMed Abstract | Publisher Full Text**
- Li XJ, et al.: As an independent unfavorable prognostic factor, IL-8 promotes metastasis of nasopharyngeal carcinoma through induction of epithelial-mesenchymal transition and activation of AKT signaling. Carcinogenesis. 2012; 33: 1302–1309.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Young LS, Dawson CW: Epstein-Barr virus and nasopharyngeal carcinoma. Chin J Cancer. 2014; 33: 581–590.
 PubMed Abstract | Publisher Full Text | Free Full Text
- Mostaan LV, et al.: Correlation between E-cadherin and CD44 adhesion molecules expression and cervical lymph node metastasis in oral tongue SCC: Predictive significance or not. Pathol. Res. Pract. 2011; 207: 448-451. PubMed Abstract | Publisher Full Text

Open Peer Review

Current Peer Review Status: 💙 🤇

Version 1

Reviewer Report 02 August 2021

https://doi.org/10.5256/f1000research.57054.r90635

© **2021 Yunus M.** This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Mohd Razif Mohamad Yunus 匝

Faculty of Medicine, Department of Otorhinolaryngology, National University of Malaysia, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia

It is a good research for the local Indonesian area and data. Reference to their own local data is excellent. The authors have done up to their capabilities at their centre.

Recommendations:

- 1. The authors may expand about the limitations of the study and why possibly due to budget, poor response from the patients etc. as the incidence of NPC in Indonesia is high.
- 2. May expand the use of having these markers in treatment strategies, possibly as follow up measures.
- 3. The target sample size should be calculated and included in the methods. This is important to get the significant results of the study. Based on the NPC incidence in Indonesia, the sample size for significant results can be calculated.
- 4. Multiple centres collection of sample from other hospital can be considered to get the numbers.
- 5. It is difficult to give conclusion as stated because the number of sample is not representative of the NPC incidence in Indonesia.

Is the work clearly and accurately presented and does it cite the current literature? Partly

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Partly

If applicable, is the statistical analysis and its interpretation appropriate?

I cannot comment. A qualified statistician is required.

Are all the source data underlying the results available to ensure full reproducibility? Partly

Are the conclusions drawn adequately supported by the results? Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: clinical head and neck oncology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 03 Aug 2021

Muhtarum Yusuf, Airlangga University, Surabaya, Indonesia

1. The authors may expand about the limitations of the study and why -possibly due to budget, poor response from the patients etc. as the incidence of NPC in Indonesia is high.

Because the research is limited in time so that the fulfillment of the minimum number of samples to pass the IHC staining on paraffin blocks is quite difficult. In addition, the researchers only examined the expression of CD44 cancer stem cells without examining CD44 activity. Therefore, the explanation and role of CD44 in NPC stem cells will be more detailed, especially when assessed based on the activity of Shh and Bmi-1 proteins.

2. May expand the use of having these markers in treatment strategies, possibly as follow up measures.

We might want to use this marker as follow up measures for NPC patients who have undergone chemotherapy. But from this study it has insignificant result so we cannot recommend CD44 as a targeted therapy yet. Therefore, further research is needed, especially those that represent each type of WHO representatively

3. The target sample size should be calculated and included in the methods. This is important to get the significant results of the study. Based on the NPC incidence in Indonesia, the sample size for significant results can be calculated.

The sample size in this study was calculated using the cross sectional research formula: Total sample size = $[(Za).^2p \cdot q] : d^2$ = $(1,96^2x 0,5 x 0,5) : 0,15^2$ = 42,38 (rounded to 43 sample)

note:

```
n = total sample size
```

Z = Standard deviation (α = 0,05 with Z = 1,96)

p = 0,5

From these calculations, the sample size is sufficient

4. Multiple centres - collection of sample from other hospital can be considered to get the numbers.

We are thinking of doing research from multicentre in order to get better external validity

5. It is difficult to give conclusion as stated because the number of sample is not representative of the NPC incidence in Indonesia.

This research would be better if it was conducted with a larger number of samples and multicentre. In addition, the sample in this study did not have an equivalent distribution of the number of WHO types. The largest sample in this study was WHO types III-IV with WHO types I and II samples not being adequately represented

Thanks to reviewer for better advice.

Competing Interests: Authors are a close professional associate of any of the authors (same profession as otorhinolaryngologist)

Reviewer Report 02 August 2021

https://doi.org/10.5256/f1000research.57054.r90636

© **2021 Farhat F.** This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



Farhat Farhat 匝

Faculty of Medicine, Department of Otorhinolaryngology-Head and Neck Surgery, Universitas Sumatera Utara, Medan, Indonesia

1. The topic for this research is interesting. For now, the recurrency of cancer including NPC is still challenging for clinicians. Exploration about the etiology of the recurrency should be done and the idea to analyze the CD44+ cancer stem cell is interesting. Associating the

CD44+ cancer stem cell with the histopathologic type is interesting due to the variation of relation with EBV and sensitivity with radiotherapy. It is good to be focused on population or geographical distribution of the NPC patients. We all know that geographical distribution has high relation with NPC incidence. It can help for mapping the cases.

- 2. The method of this research is quite clear and complete. The antibody monoclonal that is used for IHC is mentioned. The effort to decrease bias and the references for determining CD44 expression scores are also done and mentioned. Statistical analysis is also clear enough. The ethic approval from ethical committee is also mentioned in the method.
- 3. Table and Figure are quite representative. It will be good if the p value is also put on the table.
- 4. The insignificant result may be caused by several factors, and I agree that the sample size may also contribute to the result.

Is the work clearly and accurately presented and does it cite the current literature? $\ensuremath{\mathsf{Yes}}$

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others? $\ensuremath{\mathsf{Yes}}$

If applicable, is the statistical analysis and its interpretation appropriate? $\ensuremath{\mathsf{Yes}}$

Are all the source data underlying the results available to ensure full reproducibility? $\ensuremath{\mathsf{Yes}}$

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: ENT oncology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 03 Aug 2021

Muhtarum Yusuf, Airlangga University, Surabaya, Indonesia

Thank you to the reviewer for the suggestion. Authors think about the possibility of being insignificant for the result of this publication.

Competing Interests: The authors are a close professional associate of any of the authors (same professions as otorhinolaryngologist)

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000 Research